Most individuals can continue treatment comfortably with a few evidence-based adjustments, such as: Encourage a gradual dose titration
On the other hand, GIP deficiency did not seem to be pathogenic of diabetes leading to the peptide being mostly ignored after initially being discovered and isolated [20]
Preclinical research has examined GLP-1 receptor agonists in alcohol use disorder, compulsive eating, and cocaine and opioid models, with consistent reductions in substance intake and relapse-like behaviour in animals
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A
They attributed the relatively lower MA prices to the same reasons outlined by Berenson et al
